赛升药业：控股子公司取得换发《药品生产许可证》

Core Viewpoint - The company, Sai Sheng Pharmaceutical, announced that its subsidiary, Beijing Sai Er Biological Pharmaceutical Co., Ltd., has received a renewed Drug Production License from the Beijing Drug Administration, valid until October 19, 2030 [1] Group 1 - The renewed Drug Production License signifies compliance with regulatory standards, enhancing the company's operational capabilities in the pharmaceutical sector [1] - The license renewal is a critical step for the company to continue its production activities and potentially expand its market presence [1]